TCGA Bladder Cancer Study Reveals Recurrent Mutations, Possible Treatment Targets | GenomeWeb

NEW YORK (GenomeWeb News) – Genes involved in chromatin regulation are amongst those most prone to recurrent mutation in urothelial bladder cancer, according to a new Nature study from members of the Cancer Genome Atlas. Results from their large, integrated analysis hint that that pathway — and others — might serve as treatment targets for the disease in the future.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.